Topline results from the Phase 2 CELIA study of Diranersen (BIIB080) in early stage Alzheimer's disease announced at AAIC.See link: https://investors.biogen.com/news-releases/news-release-details/biogen-presents-phase-2-celia-data-aaic-demonstrating-meaningful
The European Journal of Neurology reported that 'Misfolded alpha‐synuclein in amyotrophic lateral sclerosis' was "ranked within the top 10% of most viewed papers" published in their journal. See link.See paper 'Misfolded alpha‐synuclein in amyotrophic lateral sclerosis: Implications for diagnosis and treatment' here: https://onlinelibrary.wiley.com/doi/10.1111/ene.16206